Semma Tablets 3Mg (1 Box = 3 Strips) (1 Strip = 10 Tablets)

Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1

PKR 5000.00

PKR 4750.00

You save: PKR 250.00

Quantity:

SKU: SEMMA_3MG_TAB_30S_NV

Category: Medicines

Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1. GLP-1 is a physiological hormone that has multiple actions on glucose, mediated by the GLP-1 receptors. The principal mechanism of protraction resulting in the long half-life of Semaglutide is albumin binding, which results in decreased renal clearance and protection from metabolic degradation. Furthermore, Semaglutide is stabilized against degradation by the DPP-4 enzyme. Semaglutide reduces blood glucose through a mechanism where it stimulates insulin secretion and lowers glucagon secretion, both in a glucose-dependent manner. Thus, when blood glucose is high, insulin secretion is stimulated and glucagon secretion is inhibited. The mechanism of blood glucose lowering also involves a minor delay in gastric emptying in the early postprandial phase.

Purpose

Diabetes

Ingredients

Semaglutide

Warnings

Anaphylaxis and angioedema have been reported with other GLP-1 receptor agonists. Use caution in a patient with a history of angioedema or anaphylaxis with another GLP-1 receptor agonist because it is unknown whether such patients will be predisposed to anaphylaxis with Semaglutide.
Use of GLP-1 receptor agonists may be associated with gastrointestinal adverse reactions. This is advised to be considered when treating patients, with impaired renal function as nausea, vomiting, and diarrhea may cause dehydration which could cause a deterioration of renal function.
There is no therapeutic experience in patients with congestive heart failure therefore, use of Semaglutide is not recommended in these patients.

Side Effects

Very Common : Hypoglycemia when used with insulin or sulfonylurea, nausea and diarrhea. Common : Hypoglycemia when used with other oral antidiabetics (OAD), decreased appetite, dizziness, diabetic retinopathy complications, vomiting, abdominal pain, abdominal distension, constipation, dyspepsia, gastritis, gastroesophageal reflux disease, eructation, flatulence, cholelithiasis, fatigue, increased lipase, increased amylase and weight decreased. Uncommon : Hypersensitivity, dysgeusia, increased heart rate, acute pancreatitis, delayed gastric emptying and injection site reactions. Rare : Anaphylactic reaction, intestinal obstruction and angioedema .